Drug Profile
Research programme: small molecule therapeutics - ChemBridge Corporation/Evotec SE
Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator ChemBridge Corporation; Evotec AG
- Developer ChemBridge Corporation; Evotec SE
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Germany
- 18 Feb 2011 Early research in Undefined indication in Germany (unspecified route)